Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07420959 · ClinicalTrials.gov registry record · Phase 1
ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia
A Phase 1 study, sponsored by Mayo Clinic.
- Not yet
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT07420959: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT07420959 is a Phase 1 study that has not yet begun recruiting, run by Mayo Clinic. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07420959, a Phase 1 study, has not yet begun recruiting, sponsored by Mayo Clinic.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of ABBV-383 and to see how well it works in treating patients with Waldenström macroglobulinemia that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). ABBV-383 is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Bone Marrow Aspiration
- PROCEDURE Bone Marrow Biopsy
- PROCEDURE Computed Tomography
- BIOLOGICAL Etentamig
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2026-10-25 |
| Est. Completion | 2038-10-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07420959
The ClinicalTrials.gov registry entry for NCT07420959 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07420959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07420959 about?
NCT07420959 is a clinical study titled "ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia". This phase I/II trial studies the side effects and best dose of ABBV-383 and to see how well it works in treating patients with Waldenström macroglobulinemia that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). ABBV-383 is a monoclonal antib...
What is the current status of trial NCT07420959?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2026-10-25. Estimated completion is 2038-10-25.
What interventions are being tested in trial NCT07420959?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Etentamig (BIOLOGICAL).
Who is sponsoring clinical trial NCT07420959?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.